These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 8879978)

  • 61. Cisplatin nephrotoxicity and platinum-metallothioneins: uptake and toxicity in proximal tubular cells from rat kidney.
    Boogaard PJ; Mulder GJ; Nagelkerke JF
    Contrib Nephrol; 1990; 83():208-12. PubMed ID: 2100713
    [No Abstract]   [Full Text] [Related]  

  • 62. Comparison of the novel HK-2 human renal proximal tubular cell line with the standard LLC-PK1 cell line in studying drug-induced nephrotoxicity.
    Gunness P; Aleksa K; Kosuge K; Ito S; Koren G
    Can J Physiol Pharmacol; 2010 Apr; 88(4):448-55. PubMed ID: 20555413
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Novel polymyxin derivatives are less cytotoxic than polymyxin B to renal proximal tubular cells.
    Mingeot-Leclercq MP; Tulkens PM; Denamur S; Vaara T; Vaara M
    Peptides; 2012 Jun; 35(2):248-52. PubMed ID: 22504013
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Synergistic toxicity of cyclosporin A and streptomycin in renal epithelial cell cultures.
    Walker RJ; Lazzaro VA; Duggin GG; Horvath JS; Tiller DJ
    Res Commun Chem Pathol Pharmacol; 1988 Dec; 62(3):447-60. PubMed ID: 3222524
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The application of renal cells in culture in studying drug-induced nephrotoxicity.
    Williams PD
    In Vitro Cell Dev Biol; 1989 Sep; 25(9):800-5. PubMed ID: 2793779
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Platinum compounds.
    Belani CP; Van Echo DA; Aisner J
    Curr Opin Oncol; 1989 Dec; 1(2):186-91. PubMed ID: 2489958
    [No Abstract]   [Full Text] [Related]  

  • 67. LLC-PK1 epithelia as a model for in vitro assessment of proximal tubular nephrotoxicity.
    Steinmassl D; Pfaller W; Gstraunthaler G; Hoffmann W
    In Vitro Cell Dev Biol Anim; 1995 Feb; 31(2):94-106. PubMed ID: 7735573
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Mechanisms of renal excretion of cisdichlorodiamine platinum.
    Caterson R; Etheredge S; Snitch P; Duggin G
    Res Commun Chem Pathol Pharmacol; 1983 Aug; 41(2):255-64. PubMed ID: 6685336
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Comparative impact of cephaloridine on glutathione and related enzymes in LLC-PK1, LLC-RK1, and primary cultures of rat and rabbit proximal tubule cells.
    Morin JP; Marouillat S; Lendormi C; Monteil C
    Cell Biol Toxicol; 1996 Dec; 12(4-6):275-82. PubMed ID: 9034621
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Regulation of TauT by cisplatin in LLC-PK1 renal cells.
    Han X; Chesney RW
    Pediatr Nephrol; 2005 Aug; 20(8):1067-72. PubMed ID: 15942793
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Influence of uranium(VI) speciation for the evaluation of in vitro uranium cytotoxicity on LLC-PK1 cells.
    Mirto H; Barrouillet MP; Hengé-Napoli MH; Ansoborlo E; Fournier M; Cambar J
    Hum Exp Toxicol; 1999 Mar; 18(3):180-7. PubMed ID: 10215109
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Cytotoxicity of nephrotoxic fungal toxins to kidney-derived LLC-PK1 and OK cell lines.
    Bondy GS; Armstrong CL
    Cell Biol Toxicol; 1998 Oct; 14(5):323-32. PubMed ID: 9808360
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Cisplatin, rather than oxaliplatin, increases paracellular permeability of LLC-PK1 cells via activating protein kinase C.
    Zhang Y; Yonezawa A; Nakagawa S; Imai S; Denda M; Omura T; Nakagawa T; Matsubara K
    Drug Metab Pharmacokinet; 2020 Feb; 35(1):111-116. PubMed ID: 31964622
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Evaluation of guggulsterone derivatives as novel kidney cell protective agents against cisplatin-induced nephrotoxicity.
    Lee D; Kim T; Kim KH; Ham J; Jang TS; Kang KS; Lee JW
    Bioorg Med Chem Lett; 2017 Jul; 27(14):3156-3161. PubMed ID: 28552338
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Elucidation of protective effects of oxime derivatives against cisplatin-induced cytotoxicity in LLC-PK1 kidney cells.
    Lee D; Hyuk Lee S; Lee H; Choi YK; Sung Kang K; Wook Lee J
    Bioorg Med Chem Lett; 2023 Jan; 80():129114. PubMed ID: 36574854
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Gamma-glutamyl transpeptidase accelerates tumor growth and increases the resistance of tumors to cisplatin in vivo.
    Hanigan MH; Gallagher BC; Townsend DM; Gabarra V
    Carcinogenesis; 1999 Apr; 20(4):553-9. PubMed ID: 10223181
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Platinum nephrotoxicity.
    Madias NE; Harrington JT
    Am J Med; 1978 Aug; 65(2):307-14. PubMed ID: 99034
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Synthesis and biological evaluation of chalcone analogues as protective agents against cisplatin-induced cytotoxicity in kidney cells.
    Lee D; Kim KH; Moon SW; Lee H; Kang KS; Lee JW
    Bioorg Med Chem Lett; 2015 May; 25(9):1929-32. PubMed ID: 25824663
    [TBL] [Abstract][Full Text] [Related]  

  • 79. In vitro studies on genotoxicity and cytotoxicity of the anticancer drugs cisplatin and cofplaton, a caffeine-8-ether plus cisplatinum compound.
    Vogel R; Laschinski G; Spielman H; Ehrlich W; Drevenstedt B; Klosa J; Kröger H
    Mutat Res; 1991 Dec; 264(4):225-30. PubMed ID: 1723504
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Use of flow cytometry and confocal microscopy techniques to investigate early CdCl(2)-induced nephrotoxicity in vitro.
    Alvarez-Barrientos A; O'Connor JE; Nieto Castillo R; Moreno Moreno AB; Prieto P
    Toxicol In Vitro; 2001; 15(4-5):407-12. PubMed ID: 11566571
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.